Global Insulin Biosimilars 麻豆原创 Research Report 2023

Publication ID:

PB501236870

Publication Date:

January 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
Highlights
The global Insulin Biosimilars market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Insulin Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Insulin Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Insulin Biosimilars include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Insulin Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Biosimilars.
The Insulin Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Insulin Biosimilars market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Segment by Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Segment by Application
Type I Diabetes
Type II Diabetes
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Insulin Biosimilars 麻豆原创 Overview
1.1 Product Overview and Scope of Insulin Biosimilars
1.2 Insulin Biosimilars Segment by Type
1.2.1 Global Insulin Biosimilars 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Rapid-Acting Biosimilars
1.2.3 Long-Acting Biosimilars
1.2.4 Premixed Biosimilars
1.3 Insulin Biosimilars Segment by Application
1.3.1 Global Insulin Biosimilars 麻豆原创 Value by Application: (2023-2029)
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Global Insulin Biosimilars 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Insulin Biosimilars Revenue 2018-2029
1.4.2 Global Insulin Biosimilars Sales 2018-2029
1.4.3 Global Insulin Biosimilars 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Insulin Biosimilars 麻豆原创 Competition by Manufacturers
2.1 Global Insulin Biosimilars Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Insulin Biosimilars Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Insulin Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Insulin Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Insulin Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Insulin Biosimilars, Product Type & Application
2.7 Insulin Biosimilars 麻豆原创 Competitive Situation and Trends
2.7.1 Insulin Biosimilars 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Insulin Biosimilars Players 麻豆原创 Share by Revenue
2.7.3 Global Insulin Biosimilars 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Insulin Biosimilars Retrospective 麻豆原创 Scenario by Region
3.1 Global Insulin Biosimilars 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Insulin Biosimilars Global Insulin Biosimilars Sales by Region: 2018-2029
3.2.1 Global Insulin Biosimilars Sales by Region: 2018-2023
3.2.2 Global Insulin Biosimilars Sales by Region: 2024-2029
3.3 Global Insulin Biosimilars Global Insulin Biosimilars Revenue by Region: 2018-2029
3.3.1 Global Insulin Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Insulin Biosimilars Revenue by Region: 2024-2029
3.4 North America Insulin Biosimilars 麻豆原创 Facts & Figures by Country
3.4.1 North America Insulin Biosimilars 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Insulin Biosimilars Sales by Country (2018-2029)
3.4.3 North America Insulin Biosimilars Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Insulin Biosimilars 麻豆原创 Facts & Figures by Country
3.5.1 Europe Insulin Biosimilars 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Insulin Biosimilars Sales by Country (2018-2029)
3.5.3 Europe Insulin Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Insulin Biosimilars 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Insulin Biosimilars 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Insulin Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific Insulin Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Insulin Biosimilars 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Insulin Biosimilars 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Insulin Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America Insulin Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Insulin Biosimilars 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Insulin Biosimilars 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Insulin Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa Insulin Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Insulin Biosimilars Sales by Type (2018-2029)
4.1.1 Global Insulin Biosimilars Sales by Type (2018-2023)
4.1.2 Global Insulin Biosimilars Sales by Type (2024-2029)
4.1.3 Global Insulin Biosimilars Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Insulin Biosimilars Revenue by Type (2018-2029)
4.2.1 Global Insulin Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Insulin Biosimilars Revenue by Type (2024-2029)
4.2.3 Global Insulin Biosimilars Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Insulin Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global Insulin Biosimilars Sales by Application (2018-2029)
5.1.1 Global Insulin Biosimilars Sales by Application (2018-2023)
5.1.2 Global Insulin Biosimilars Sales by Application (2024-2029)
5.1.3 Global Insulin Biosimilars Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Insulin Biosimilars Revenue by Application (2018-2029)
5.2.1 Global Insulin Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Insulin Biosimilars Revenue by Application (2024-2029)
5.2.3 Global Insulin Biosimilars Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Insulin Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi S.A.
6.1.1 Sanofi S.A. Corporation Information
6.1.2 Sanofi S.A. Description and Business Overview
6.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sanofi S.A. Insulin Biosimilars Product Portfolio
6.1.5 Sanofi S.A. Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Corporation Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Boehringer Ingelheim Insulin Biosimilars Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 Eli Lilly & Co.
6.3.1 Eli Lilly & Co. Corporation Information
6.3.2 Eli Lilly & Co. Description and Business Overview
6.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly & Co. Insulin Biosimilars Product Portfolio
6.3.5 Eli Lilly & Co. Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novo Nordisk A/S Insulin Biosimilars Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Biocon
6.5.1 Biocon Corporation Information
6.5.2 Biocon Description and Business Overview
6.5.3 Biocon Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Biocon Insulin Biosimilars Product Portfolio
6.5.5 Biocon Recent Developments/Updates
6.6 Geropharm
6.6.1 Geropharm Corporation Information
6.6.2 Geropharm Description and Business Overview
6.6.3 Geropharm Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Geropharm Insulin Biosimilars Product Portfolio
6.6.5 Geropharm Recent Developments/Updates
6.7 Wockhardt
6.6.1 Wockhardt Corporation Information
6.6.2 Wockhardt Description and Business Overview
6.6.3 Wockhardt Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Wockhardt Insulin Biosimilars Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
6.8 Gan&Lee Pharmaceuticals
6.8.1 Gan&Lee Pharmaceuticals Corporation Information
6.8.2 Gan&Lee Pharmaceuticals Description and Business Overview
6.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolio
6.8.5 Gan&Lee Pharmaceuticals Recent Developments/Updates
6.9 The United Laboratories International
6.9.1 The United Laboratories International Corporation Information
6.9.2 The United Laboratories International Description and Business Overview
6.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 The United Laboratories International Insulin Biosimilars Product Portfolio
6.9.5 The United Laboratories International Recent Developments/Updates
6.10 Tonghua Dongbao Pharmaceutical
6.10.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.10.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolio
6.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Insulin Biosimilars Industry Chain Analysis
7.2 Insulin Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Insulin Biosimilars Production Mode & Process
7.4 Insulin Biosimilars Sales and 麻豆原创ing
7.4.1 Insulin Biosimilars Sales Channels
7.4.2 Insulin Biosimilars Distributors
7.5 Insulin Biosimilars Customers
8 Insulin Biosimilars 麻豆原创 Dynamics
8.1 Insulin Biosimilars Industry Trends
8.2 Insulin Biosimilars 麻豆原创 Drivers
8.3 Insulin Biosimilars 麻豆原创 Challenges
8.4 Insulin Biosimilars 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.